Antibe Therapeutics Inc. (OTCMKTS:ATBPF – Get Free Report) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 8,900 shares, a drop of 73.1% from the February 29th total of 33,100 shares. Based on an average trading volume of 88,700 shares, the short-interest ratio is presently 0.1 days.
Antibe Therapeutics Trading Down 1.6 %
Shares of OTCMKTS:ATBPF opened at $0.32 on Thursday. The firm has a market cap of $16.85 million, a price-to-earnings ratio of -1.27 and a beta of 0.57. The business has a fifty day simple moving average of $0.58 and a 200 day simple moving average of $0.55. Antibe Therapeutics has a 1 year low of $0.24 and a 1 year high of $0.89.
Antibe Therapeutics (OTCMKTS:ATBPF – Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. On average, sell-side analysts forecast that Antibe Therapeutics will post -0.3 EPS for the current year.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on ATBPF
Antibe Therapeutics Company Profile
Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Further Reading
- Five stocks we like better than Antibe Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Best Bear Market Funds: Top 3 Investment Options to Consider
- How to Use the MarketBeat Dividend Calculator
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- Airline Stocks – Top Airline Stocks to Buy Now
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.